Section III: Emerging technologies/models for MCC research

Chair: Weng-Onn Lui (Stockholm, Sweden)

09:00-09:30 Camilla Engblom (Stockholm, Sweden)
Mapping antigen receptors in tissues using spatial transcriptomics

09:30-10:00    Simon Fredriksson (Stockholm, Sweden)
Protein interactomics of single cells by Proximity Networks for translational research

10:00-10:30    Tobias Reiff (Düsseldorf, Germany)
Personalized fly avatar technology for the investigation of tumour biology and therapy development

10:30-11:00    Coffee break   

11:00-11:15   Short communication 6
Speaker and title TBD

11:15-11:30   Krista Lachance, Rima Kulikauskas, Candice Church and Paul Nghiem (Seattle, WA, USA)
How can the Merkel cell carcinoma collaborative (MC3) Institute help advance our field?

Session IV: Immunotherapy and clinical trials

Chair: Jürgen Becker (Essen, Germany) and Lisa Villabona (Stockholm, Sweden)

11:30-12:00    Anna-Sophia Leven (Essen, Germany)
Adjuvant and neo-adjuvant therapy of MCC

12:00-12:30    Shailender Bhatia (Seattle, WA, USA)
Intra-tumoral immunotherapies for MCC

12:30-13:30    Lunch                

13:30-14:00    Celeste Lebbe (Paris, France)
Benefits of immunotherapy in advanced MCC, updates on clinical trials and real world data

14:00-14:30    Paul Nghiem (Seattle, WA, USA)
The MATRiX-2 trial for ICI-refractory MCC: Can an ATR inhibitor improve patient outcomes if added to ICI and a single dose of radiation?

14:30-14:45   George Lodde (Essen, Germany)
Survival Outcome of MCC’s initial locoregional treatment in the pre- and immunotherapy era

14:45-15:00   Kelly Harms (Ann Arbor, MI, USA)
Adjuvant single fraction radiotherapy to the resected primary tumor site and stage IIIA regional disease results in high locoregional control in Merkel cell carcinoma

Final remarks

15:00-15:15    Weng-Onn Lui, John Paoli, Nicole Fischer, Jürgen Becker, Lisa Villabona & Thibault Kervarrec